aTrial arrhythmias in inhEriTed aRrhythmIa Syndromes: results from the TETRIS study
Authors:
- Giulio ConteGCGiulio Conte
- Marco BergontiMBMarco Bergonti
- Vincent ProbstVPVincent Probst
- Hiroshi MoritaHMHiroshi Morita
- Jacob Tfelt-HansenJTJacob Tfelt-Hansen
- Elijah R BehrEBElijah R Behr
- Kusano KengoKKKusano Kengo
- Elena ArbeloElena Arbelo
- Lia CrottiLCLia Crotti
- Georgia Sarquella-BrugadaGSGeorgia Sarquella-Brugada
- Arthur A M WildeAWArthur A M Wilde
- Leonardo CalòLCLeonardo Calò
Open Access
- 11 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (12)
Abstract
Aims: Little is known about the distribution and clinical course of patients with inherited arrhythmia syndrome (IAS) and concomitant atrial arrhythmias (AAs). The aim of the study is (i) to characterize the distribution of AAs in patients with IAS and (ii) evaluate the long-term clinical course of these patients. Methods and results: An international multicentre study was performed and involved 28 centres in 16 countries. Inclusion criteria were (i) IAS and (ii) electrocardiographic documentation of AAs. The primary endpoint was a composite of sudden cardiac death, sustained ventricular arrhythmias (VAs), or appropriate implantable cardioverter defibrillator (ICD) interventions. Strokes, inappropriate ICD shocks due to AAs, and the occurrence of sinus node dysfunction were assessed. A total of 522 patients with IAS and AAs were included. Most patients were diagnosed with Brugada syndrome (n = 355, 68%) and long QT syndrome (n = 93, 18%). The remaining patients (n = 71, 14%) presented with short QT syndrome, early repolarization syndrome, catecholaminergic polymorphic ventricular tachycardia, progressive cardiac conduction diseases, or idiopathic ventricular fibrillation. Atrial fibrillation was the most prevalent AA (82%), followed by atrial flutter (9%) and atrial tachycardia (9%). Atrial arrhythmia was the first clinical manifestation of IAS in 52% of patients. More than one type of AA was documented in 23% of patients. Nine patients (3%) experienced VA before the diagnosis of IAS due the use of anti-arrhythmic medications taken for the AA. The incidence of the primary endpoint was 1.4% per year, with a two-fold increase in patients who experienced their first AA before the age of 20 (odds ratio 2.2, P = 0.043). This was consistent across the different forms of IAS. Inappropriate ICD shock due to AAs was reported in 2.8% of patients, strokes in 4.4%, and sinus node dysfunction in 9.6%. Conclusion: Among patients with IAS and AAs, AA is the first clinical manifestation in about half of the cases, with more than one form of AAs present in one-fourth of the patients. The occurrence of AA earlier in life may be associated with a higher risk of VAs. The occurrence of stroke and sinus node dysfunction is not infrequently in this cohort.Keywords
Funding Information
- Swiss National Science Foundation (PZ00P3_180055)
This publication has 20 references indexed in Scilit:
- Atrial fibrillation: the role of common and rare genetic variantsEuropean Journal of Human Genetics, 2013
- Genetic testing in heritable cardiac arrhythmia syndromesCurrent Opinion in Cardiology, 2013
- A KCNJ8 mutation associated with early repolarization and atrial fibrillationEP Europace, 2012
- Monogenic atrial fibrillation as pathophysiological paradigmsCardiovascular Research, 2010
- New-onset atrial fibrillation as first clinical manifestation of latent Brugada syndrome: prevalence and clinical significanceEuropean Heart Journal, 2009
- Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillationHeart Rhythm, 2009
- Prevalence of early-onset atrial fibrillation in congenital long QT syndromeHeart Rhythm, 2008
- Stretch-Sensitive KCNQ1MutationJACC, 2007
- Short QT syndrome: clinical findings and diagnostic-therapeutic implicationsEuropean Heart Journal, 2006
- Brugada Syndrome: Report of the Second Consensus ConferenceCirculation, 2005